Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. [electronic resource]
Producer: 20170717Description: 364-371 p. digitalISSN:- 1938-0666
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Alkylating -- administration & dosage
- Biomarkers, Pharmacological -- metabolism
- Breast Neoplasms -- drug therapy
- DNA-Binding Proteins -- metabolism
- Dioxoles -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Endonucleases -- metabolism
- Female
- Humans
- Infusions, Intravenous
- Middle Aged
- Nuclear Proteins -- metabolism
- Receptor, ErbB-2 -- metabolism
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Survival Analysis
- Tetrahydroisoquinolines -- administration & dosage
- Trabectedin
- Transcription Factors -- metabolism
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.